Do You Know or Have a Child or Teenager with Fragile X Syndrome (FXS)?

NOW ENROLLING

A clinical trial in boys and girls with FXS ages 3 through 17*

Currently, there are no approved treatments specifically for FXS. We are trying to change that and are now enrolling in a new study called the CONNECT-FX study. An investigational drug called ZYN002 is being studied to determine if it can help manage some of the most common behavioral symptoms associated with FXS.

ABOUT THE STUDY

• ZYN002 is a gel which is applied to the skin twice a day.
• Study related medical exams, study medication and reimbursement of reasonable study-related costs, such as travel and incidental expenses, will be supplied to qualified participants at no cost.
• Participants who complete this study may have an opportunity to enroll in a 1 year follow-on study, where everyone will receive ZYN002, study related medical exams and reimbursement of reasonable study related travel.

TO LEARN MORE, PLEASE CONTACT

IRB00173746
PI: Dejan Budimorivc, MD
Kennedy Krieger Institute
Clinical Trials Unit
Researchtrials@kennedykrieger.org

*Additional criteria apply